BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34967562)

  • 21. Recurrent TP53 missense mutation in cancer patients of Arab descent.
    Zick A; Kadouri L; Cohen S; Frohlinger M; Hamburger T; Zvi N; Plaser M; Avital E; Breuier S; Elian F; Salah A; Goldberg Y; Peretz T
    Fam Cancer; 2017 Apr; 16(2):295-301. PubMed ID: 27866339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
    Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
    Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
    Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
    Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline Genetic Features of Young Individuals With Colorectal Cancer.
    Stoffel EM; Koeppe E; Everett J; Ulintz P; Kiel M; Osborne J; Williams L; Hanson K; Gruber SB; Rozek LS
    Gastroenterology; 2018 Mar; 154(4):897-905.e1. PubMed ID: 29146522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular analysis of the APC and MUTYH genes in Galician and Catalonian FAP families: a different spectrum of mutations?
    Gómez-Fernández N; Castellví-Bel S; Fernández-Rozadilla C; Balaguer F; Muñoz J; Madrigal I; Milà M; Graña B; Vega A; Castells A; Carracedo A; Ruiz-Ponte C
    BMC Med Genet; 2009 Jun; 10():57. PubMed ID: 19531215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
    Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
    Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of oncogenesis in colon versus rectal cancer.
    Kapiteijn E; Liefers GJ; Los LC; Kranenbarg EK; Hermans J; Tollenaar RA; Moriya Y; van de Velde CJ; van Krieken JH
    J Pathol; 2001 Sep; 195(2):171-8. PubMed ID: 11592095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
    Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
    J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients.
    Steinke V; Rahner N; Morak M; Keller G; Schackert HK; Görgens H; Schmiegel W; Royer-Pokora B; Dietmaier W; Kloor M; Engel C; Propping P; Aretz S;
    Eur J Hum Genet; 2008 May; 16(5):587-92. PubMed ID: 18301448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simplifying the detection of MUTYH mutations by high resolution melting analysis.
    López-Villar I; Ayala R; Wesselink J; Morillas JD; López E; Marín JC; Díaz-Tasende J; González S; Robles L; Martínez-López J
    BMC Cancer; 2010 Aug; 10():408. PubMed ID: 20687945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in patients with multiple polyposis.
    Lejeune S; Guillemot F; Triboulet JP; Cattan S; Mouton C; ; Porchet N; Manouvrier S; Buisine MP
    Hum Mutat; 2006 Oct; 27(10):1064. PubMed ID: 16941501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mutational comparison of adult and adolescent and young adult (AYA) colon cancer.
    Tricoli JV; Boardman LA; Patidar R; Sindiri S; Jang JS; Walsh WD; McGregor PM; Camalier CE; Mehaffey MG; Furman WL; Bahrami A; Williams PM; Lih CJ; Conley BA; Khan J
    Cancer; 2018 Mar; 124(5):1070-1082. PubMed ID: 29194591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cellular and molecular deregulations driving the metastatic phenotype].
    Zeitoun G
    Med Sci (Paris); 2009 Mar; 25 Spec No 1():29-32. PubMed ID: 19361408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
    Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
    Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
    Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
    Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.